Tropical Infectious Disease Consortium: Sustaining, Expanding and Accelerating Product Development

Lead Research Organisation: Liverpool School of Tropical Medicine

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

publication icon
Edwards T (2017) Analytical and clinical performance of a Chikungunya qRT-PCR for Central and South America. in Diagnostic microbiology and infectious disease

publication icon
Ismail HM (2016) Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. in Proceedings of the National Academy of Sciences of the United States of America

 
Description External Scientific Advisory Board Member for the German Centre for Infection Research
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
 
Description External advice to major funder with regard to antimalarial drug discovery projects
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Macrofilaricide Drug Accelerator (MacDA)
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Member of the MMV External Scientific Advisory Board 2017 to date
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Membership of the Structure-guided Drug Discovery Coalition
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description • UK management committee member for COST Action CM1307, 'Targeted chemotherapy towards diseases caused by endoparasites" - 2014- to date
Geographic Reach Europe 
Policy Influence Type Influenced training of practitioners or researchers
URL http://www.costcm1307.org/CM1307/Home.html
 
Description Co-funding from Industry
Amount £70,000 (GBP)
Organisation Vaccitech Ltd 
Sector Private
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 11/2016 
End 06/2017
 
Description Confidence in Concept (CiC) by MRC
Amount £46,750 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2015 
End 03/2017
 
Description Global Challenges Research Fund
Amount £502,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2017 
End 04/2019
 
Description Grand Challenge Explorations Phase II
Amount $141,916 (USD)
Organisation Bill and Melinda Gates Foundation 
Sector Charity/Non Profit
Country United States of America
Start 02/2017 
End 02/2019
 
Description MRC
Amount £40,000 (GBP)
Organisation Medical Research Council (MRC) 
Department MRC Confidence in Concept Scheme
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2015 
End 08/2016
 
Description MRC Studentship
Amount £50,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2016 
End 07/2019
 
Description UK Vaccine Network
Amount £1,866,981 (GBP)
Funding ID R45331/CN001 
Organisation Department of Health Social Services and Public Safety (DHSSPS) 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2016 
End 08/2019
 
Description Zika Rapid Response
Amount £150,000 (GBP)
Funding ID ZK/16-025 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2016 
End 09/2017
 
Title Genedrive kdr probes 
Description Probes for detecting resistance mutations in pyrethroid target (kdr) 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Still being validated 
 
Title OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens 
Description Background The search for highly effective anti-malarial therapies has gathered pace and recent years have seen a number of promising single and combined therapies reach the late stages of development. A key drug development challenge is the need for early assessment of the clinical utility of new drug leads as it is often unclear for developers whether efforts should be focused on efficacy or metabolic stability/exposure or indeed whether the continuation of iterative QSAR (quantitative structure-activity and relationships) cycles of medicinal chemistry and biological testing will translate to improved clinical efficacy. Pharmacokinetic and pharmacodynamic (PK/PD)-based measurements available from in vitro studies can be used for such clinical predictions. However, these predictions often require bespoke mathematical PK/PD modelling expertise and are normally performed after candidate development and, therefore, not during the pre-clinical development phase when such decisions need to be made. Methods An internet-based tool has been developed using STELLA® software. The tool simulates multiple differential equations that describe anti-malarial PK/PD relationships where the user can easily input PK/PD parameters. The tool utilizes a simple stop-light system to indicate the efficacy of each combination of parameters. This tool, called OptiMal-PK, additionally allows for the investigation of the effect of drug combinations with known or custom compounds. Results The results of simulations obtained from OptiMal-PK were compared to a previously published and validated mathematical model on which this tool is based. The tool has also been used to simulate the PK/PD relationship for a number of existing anti-malarial drugs in single or combined treatment. Simulations were predictive of the published clinical parasitological clearance activities for these existing therapies. Conclusions OptiMal-PK is designed to be implemented by medicinal chemists and pharmacologists during the pre-clinical anti-malarial drug development phase to explore the impact of different PK/PD parameters upon the predicted clinical activity of any new compound. It can help investigators to identify which pharmacological features of a compound are most important to the clinical performance of a new chemical entity and how partner drugs could potentially improve the activity of existing therapies. 
Type Of Material Computer model/algorithm 
Year Produced 2016 
Provided To Others? Yes  
Impact The software has been used by a number of users for both teaching and research purposes. The use of the model has lowered the number of animal experiments in my laboratory but it is difficult to estimate how many in vivo experiments it has reduced externally. We are currently working to promote the on-line tool. 
URL http://optimalpk.lstmed.ac.uk
 
Title prospective evaluations of novel RT-PCR assays for the diagnosis of dengue and chikungunya 
Description We have conducted prospective evaluations of novel RT-PCR assays for the diagnosis of dengue and chikungunya in Ecuador, Guatemala and Brazil. The new assays were compared to the reference standard in the national surveillance laboratories (the CDC assays for these viruses). 
Type Of Material Database/Collection of data 
Year Produced 2015 
Provided To Others? Yes  
Impact We are currently conducting sequencing of selected samples to confirm our findings. Pending final confirmation, the assays developed (by LSTM in collaboration with Qiagen) are as sensitive and specific as the reference standard 
 
Description Alder Hey Collaboration 
Organisation Alder Hey Children's NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution We have processed blood samples taken from children admitted to PICU with sepsis and healthy child volunteers (blood sample taken under general anaesthetic for routine surgery). We have used our innovative assay that requires less than 2ml blood to measure neutrophil function with and without the immunostimulatory drug P4 peptide. We have processed and saved excess plasma in order to facilitate further analysis. We provided the clinical protocols and platform for the study based on our adult study used to validate the assay that we refined during the course of the award. We made available our CRN Portfolio sponsorship gained through funding of the study in order to facilitate research nurse screening and recruitment if patients.
Collaborator Contribution Alder Hey wrote the ethical amendment and child information / parental consent forms for the study. Subsequently Alder Hey have screened, consented and took blod form children before transporting it to LSTM for analysis.
Impact We have currently recruited all 10 volunteers and 7/10 patients with sepsis. We plan to use this information to generate peer reviewed papers
Start Year 2015
 
Description Avacta 
Organisation Avacta Group
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Contacts made following Adhiron CiC project and meeting held in Leeds for networking Adhiron technology. Avacta have interests in venoms,thus connections made with Dr Harrison and Venom Research Unit to develop reserach project
Collaborator Contribution Avacta are preparing MOU and in IP nergotiations to prepare the ground for funding of a venom reserach project
Impact Confidentiality agreement
Start Year 2015
 
Description BioGene and QuRapID qPCR system 
Organisation BioGene
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Design of primer and probes sets for the identification of anti-microbial resistance markers. Collection of bacterial isolates with AMR markers in Malawi.
Collaborator Contribution Use of Visual OMP for primer/probe design. Test rig of the QuRapID system delivered to LSTM PhD student Kavit Shah will start in March 2017 (student and bench fees to LSTM) Support with development of molecular system and transfer to qurapid.
Impact Publications have been added to relevant section on research fish. IP file in preparation for arboviral assay
Start Year 2015
 
Description Cambridge Collaboration 
Organisation University of Cambridge
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution We have provided (under NDA) the SOPs for the whole blood phagocytosis assay to Dr Andrew Conway-Morris who is an international expert in innate immune function in sepsis.
Collaborator Contribution Dr Conway-Morris is investigating a number of neutrophil function assays as part of his work and will compare our assay against other established assays (e.g. zymosan) in an attempt to determine optimal measures.
Impact None yet
Start Year 2016
 
Description Co-developed of products by LSTM and Qiagen (In Vitro Diagnostics) 
Organisation Qiagen
Country Netherlands, Kingdom of the 
Sector Private 
PI Contribution Assay development, initial assay validation and testing of the rt-PCR assay in surveillance laboratories, Multiplex assay optimisation, and HDA assay development.
Collaborator Contribution Qiagen made a significant contribution to this project including a rotor gene qPCR system with 5 channel detection. This system has a transfer price of ~£25,000. All qPCR reaction mix, viral RNA extraction kits will be provided free of charge throughout the project, representing a significant outlay of about £15,000. Qiagen will also cover the costs of the CE mark request.
Impact Develop improved diagnostic assays for the simultaneous detection of CHK and dengue viruses. The outcomes expected are: 1. A multiplexed CHKV and DENV rt-PCR test, capable of the sensitive detection of both viruses and differentiation of DENV serotypes, which will be IVD CE certified for commercial release. 2. Performance data of the assay generated during comparative tests with "in house" rt-PCR assays and commercial ELISA tests on prospective fever cases in Ecuador and Brazil. 3. Extracted RNA from clinical specimens to enable the development of the qPCR and HDA assays at LSTM. 4. Design and initial testing of an isothermal HDA assay for CHKV. 5. Publications in international, peer reviewed, high impact factor journals.
Start Year 2015
 
Description Collaboration to accelerate development of vaccines against MERS-CoV 
Organisation M.C.I Animal Health
Country Morocco, Kingdom of 
Sector Private 
PI Contribution My research team has contributed a leading rationally designed vaccine candidate, that has already shown promise in preliminary immunogenicity studies.
Collaborator Contribution Vincent Munster's group at NIAID's Rocky Mountain Laboratories is testing the efficacy of the vaccine using his established transgenic mouse model. IRED in Chad is providing camel immunisation and immunogenicity assessment. Vaccitech Limited, a recent University of Oxford spin-out with exclusive rights to our MERS vaccine, has provided co-funding to support camel challenge studies in Morocco. We have sent vaccine to both these institutions, and they will send back results from mutually agreed study designs.
Impact A single dose of the vaccine administered intramuscularly or intranasally has been shown to provide 100% efficacy against lethal challenge in mice. Analysis of antibody titres, viral titres and histopathology are currently underway. Dromedary camels are now being recruited into the study at IRED, Chad and vaccine and consumable shipment will soon commence. We expect to immunise in December 2016, with results expected as from January 2017.
Start Year 2016
 
Description Collaboration to accelerate development of vaccines against MERS-CoV 
Organisation National Institute of Allergy and Infectious Diseases (NIAID)
Department Rocky Mountain Laboratories
Country United States of America 
Sector Public 
PI Contribution My research team has contributed a leading rationally designed vaccine candidate, that has already shown promise in preliminary immunogenicity studies.
Collaborator Contribution Vincent Munster's group at NIAID's Rocky Mountain Laboratories is testing the efficacy of the vaccine using his established transgenic mouse model. IRED in Chad is providing camel immunisation and immunogenicity assessment. Vaccitech Limited, a recent University of Oxford spin-out with exclusive rights to our MERS vaccine, has provided co-funding to support camel challenge studies in Morocco. We have sent vaccine to both these institutions, and they will send back results from mutually agreed study designs.
Impact A single dose of the vaccine administered intramuscularly or intranasally has been shown to provide 100% efficacy against lethal challenge in mice. Analysis of antibody titres, viral titres and histopathology are currently underway. Dromedary camels are now being recruited into the study at IRED, Chad and vaccine and consumable shipment will soon commence. We expect to immunise in December 2016, with results expected as from January 2017.
Start Year 2016
 
Description Collaboration to accelerate development of vaccines against MERS-CoV 
Organisation Vaccitech Ltd
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution My research team has contributed a leading rationally designed vaccine candidate, that has already shown promise in preliminary immunogenicity studies.
Collaborator Contribution Vincent Munster's group at NIAID's Rocky Mountain Laboratories is testing the efficacy of the vaccine using his established transgenic mouse model. IRED in Chad is providing camel immunisation and immunogenicity assessment. Vaccitech Limited, a recent University of Oxford spin-out with exclusive rights to our MERS vaccine, has provided co-funding to support camel challenge studies in Morocco. We have sent vaccine to both these institutions, and they will send back results from mutually agreed study designs.
Impact A single dose of the vaccine administered intramuscularly or intranasally has been shown to provide 100% efficacy against lethal challenge in mice. Analysis of antibody titres, viral titres and histopathology are currently underway. Dromedary camels are now being recruited into the study at IRED, Chad and vaccine and consumable shipment will soon commence. We expect to immunise in December 2016, with results expected as from January 2017.
Start Year 2016
 
Description Collaboration with Butantan 
Organisation Instituto Butantan
Country Brazil, Federative Republic of 
Sector Public 
PI Contribution We established collaborative links with the reference surveillance centres for the State of Sergipe and with Butantan Institute (Sao Paulo, Brazil) for the development of dengue, chikungunya and zika molecular assays
Collaborator Contribution Development of dengue, chikungunya and zika molecular assays
Impact Development of molecular assays in progress.
Start Year 2015
 
Description Collaboration with Smith College 
Organisation Smith College
Country United States of America 
Sector Academic/University 
PI Contribution We are setting up experimental infections and providing samples for Smith College to evaluate new methodoogies for detection of parasite DNA in excreta
Collaborator Contribution Smith College is assisting with sample processing and applying new methodologies to the detection of parasite DNA in mosquito feces
Impact Abstracts submission to ASTMH meeting in 2016. Grant submission to Bill and Melinda Gates Foundation, Grant submisison to GCRF
Start Year 2015
 
Description Collaboration with Xeroshield 
Organisation Xeroshield
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Expertise in vector behaviour and molecular xenomonitoring
Collaborator Contribution Expertise in product development and design ideas
Impact This collaboration began in March 2016 and we have held one preliminary meeting with partners. Bruce Alexander visited my group on 9th March 2016 and we have finalised a plan for research activities.
Start Year 2016
 
Description Epistem 
Organisation Epistem
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Development of diagnostic probes for kdr resistance in An. gambiae
Collaborator Contribution Production of probes for Genedrive system
Impact Diagnostic probes for kdr resistance, pilot data for proof of principle use of probes with Genedrive technology.
Start Year 2014
 
Description Godrej Group parnership 
Organisation Epistem
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Developed an Indo-UK partnership to develop new diagnostics for insecticide resistance
Collaborator Contribution Godrej are the largest producer of houshold insecticide products in India. They are providing a product market and in country facilities for field research. The UK partner, Epistem, are producing the technology for new product development and providing exprtise and materials for the project.
Impact Early stage of project, no outputs as yet.
Start Year 2015
 
Description Godrej Group parnership 
Organisation Godrej Group
Country India, Republic of 
Sector Private 
PI Contribution Developed an Indo-UK partnership to develop new diagnostics for insecticide resistance
Collaborator Contribution Godrej are the largest producer of houshold insecticide products in India. They are providing a product market and in country facilities for field research. The UK partner, Epistem, are producing the technology for new product development and providing exprtise and materials for the project.
Impact Early stage of project, no outputs as yet.
Start Year 2015
 
Description Joint PhD Student with RedX Pharma 
Organisation Redx Pharma Plc
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution This is a joint initiative between LSTM and RedX Pharma to recruit a PhD student to undertake a project at Liverpool and Alderley Park
Collaborator Contribution This is a joint initiative between LSTM and RedX Pharma to recruit a PhD student to undertake a project at Liverpool and Alderley Park
Impact None as yet
Start Year 2016
 
Description KIIT 
Organisation Kalinga Institute of Industrial Technology (KIIT) University
Country India, Republic of 
Sector Academic/University 
PI Contribution Links made through collaboration with Godrej Industries to develop a three way Industry - UK/India academic partnership for research and training.
Collaborator Contribution KIIT set-up high level meeting with LSTM Director (Hemingway) and Godrej to initiate talks on partnershp opportunities
Impact MOU and high level meetings with LSTM/Godrej/KIIT management. Multidisciplinary, Educational/ research/ industry
Start Year 2016
 
Description MRC CiC PDE project GSK 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Screening PDE inhibitors for activity against malaria parasites
Collaborator Contribution Provision of compounds
Impact No outputs as yet. Data are being generated.
Start Year 2015
 
Description MRC CiC PDE project Pfizer 
Organisation Pfizer Inc
Country United States of America 
Sector Private 
PI Contribution Screening PDE inhibitors for activity against malaria parasites
Collaborator Contribution Provision of compounds (still awaiting delivery)
Impact No outputs as yet
Start Year 2015
 
Description MRC CiC PDE project Salvensis 
Organisation Salvensis
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution We work together on screening GSK and Pfizer PDE inhibitors for activity against malaria parasites
Collaborator Contribution Chemistry and drug discovery expertise.
Impact No outputs as yet
Start Year 2015
 
Description MRC_CiC_CRro_nanoP 
Organisation Blueberry Therapeutics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution The phase based at LSTM commenced on 1st April 2016. We have developed a model for evaluating the intracellular compartment during Salmonella Typhi infection and are currently completing experiments using ceftriaxone/nanopolymer combinations. This work is on course to finish on time at the end of Septmeber 2016.
Collaborator Contribution Coformuations of ceftriaxone with nanopolymer - this work is now complete
Impact Research still in progress, but as of February 2017 is nearing completion. Stable model of macrophage infection by S. Typhi created and observed on high throughput imaging platforms. Experimental infection and treatment of cell lines now complete and data being analysed.
Start Year 2015
 
Description MRC_CiC_CRro_nanoP 
Organisation Blueberry Therapeutics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Unchanged from previous report
Collaborator Contribution Unchanged from previous report
Impact Research still in progress, but as of February 2017 is nearing completion. Stable model of macrophage infection by S. Typhi created and observed on high throughput imaging platforms. Experimental infection and treatment of cell lines now complete and data being analysed.
Start Year 2015
 
Description Media perfusion assay development for Leishmaniasis 
Organisation Kirkstall Ltd
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution I have used the media perfusion system bought from Kirkstall Ltd to conduct an in-depth analysis of how the process of infection with Leishmania parasites is effected by media perfusion, used to simulate both interstitial fluid flow and blood flow. I have used the QV900 system to test four standard drugs against infected macrophages in comparison with a static control. I have conducted drug accumulation studies in the system to try and elucidate the reasons for the results we have seen previously.
Collaborator Contribution Kirkstall Ltd have provided training and support of use of the media perfusion systems they manufacture. They have helped design products to suit our experimental needs and helped us gain many useful contacts in the research area.
Impact Experimentation with the media perfusion system to study the effect of media flow simulating either interstitial or blood fluid flow has been shown to reduce the overall infection caused by Leishmania parasites when compared to a static system. The higher the flow rate the lower the infection is overall after 72 hours of incubation. When testing standard drugs in this system we have found that the media perfusion alters the potency of the drugs activity. To achieve the same reduction in parasitaemia a higher concentration of drug must be used in the flow system. To enhance our understanding we have conducted drug accumulation studies that show less drug is accumulated under flow conditions.
Start Year 2013
 
Description Neutrophil bead assay: Paediatric validation 
Organisation Alder Hey Children's NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Alder Hey: Two senior investigators have partnered with us to provide access to samples from septic children in order to extend the usefulness of the assay into this age group Clatterbridge: Commitment from oncologist to assessing the potential of this assay for identifying patients at risk of neutropenic sepsis
Collaborator Contribution Alder Hey: Development of paediatric protocol, and submission of REC application. Commitment of nursing support to consent and obtain blood samples Clatterbridge: Collaborative development of a sampling strategy to identify patients with haematological malignancies receiving initial immunosuppressive treatment. This will be developed into an application for further funds to enable cross-sectional sampling of high risk patients in which the utility of the assay can be assessed
Impact No output yet
Start Year 2015
 
Description Neutrophil bead assay: Paediatric validation 
Organisation The Clatterbridge Cancer Centre NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Alder Hey: Two senior investigators have partnered with us to provide access to samples from septic children in order to extend the usefulness of the assay into this age group Clatterbridge: Commitment from oncologist to assessing the potential of this assay for identifying patients at risk of neutropenic sepsis
Collaborator Contribution Alder Hey: Development of paediatric protocol, and submission of REC application. Commitment of nursing support to consent and obtain blood samples Clatterbridge: Collaborative development of a sampling strategy to identify patients with haematological malignancies receiving initial immunosuppressive treatment. This will be developed into an application for further funds to enable cross-sectional sampling of high risk patients in which the utility of the assay can be assessed
Impact No output yet
Start Year 2015
 
Description Novel antibiotic nano formulations 
Organisation Blueberry Therapeutics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Imaging and PK-PD platform to screen novel antibiotic formulations against Salmonella
Collaborator Contribution nano-formulation expertise and materials
Impact none yet
Start Year 2015
 
Description PK/PD studies ( Drug accumulation) 
Organisation Pharmidex
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Drug accumulation studies were conducted using a media perfusion system. LSHTM used the media perfusion system and conducted a drug assay that was then placed under flow conditions to compare to a static system. LSHTM completed the assay and extracted drug samples from the cells after different times.
Collaborator Contribution Pharmidex took the samples and analysed them to find exact drug concentrations in the nanomolar range.
Impact Drug accumulation studies have been completed for two standard drugs. A significant difference is seen in the concentration of drug within the cells between the static and the flow systems.
Start Year 2016
 
Description VIT 
Organisation Vellore Institute of Technology (VIT) University
Country India, Republic of 
Sector Academic/University 
PI Contribution Research presentation and visit to VIT in 2014, leading to research and teaching links with Dept of Nanobiotechnology. Made links between LSTM International Education and Knowledge Exchange Initiatives (Michael Lurie) and VIT Director, International Relations for institutional cooperation and student exchange
Collaborator Contribution Awarded Adjunct Professorship to M Paine. Progressed instututional agreements.
Impact Adjunct Professorship (M Paine) MOU High level meeting (Nov 2015) for Institutional teaching partnership Multidisciuplinary collaboraton - Research/ educational
Start Year 2014
 
Description Invited Speaker at 1st International Congress of Vector-Borne Diseases. 10-11 Sep 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I was invited to deliver a lecture on Vector-Borne diseases and discuss the research and progress of my group, focusing on vaccine development. Conference was in Zamora, Michoacan, Mexico. More than 500 attendees including the ministry of Health of Mexico and Michoacana, as well as postgraduate students and practitioners.
Year(s) Of Engagement Activity 2016
 
Description Invited Speaker at the "Closing the Global Health Divide through Partnership Driven Innovation Meeting" 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The event represented a collective call for greater cross-border and cross-sector collaboration to ensure global preparedness for the inevitable resurgence of infectious diseases that disproportionally affect the poorest of the poor in developing countries. A series of presentations and interactive panels articulated the need for partnerships in global health and explored the challenges associated with R&D for infectious diseases.
Year(s) Of Engagement Activity 2014
 
Description Kensington and Chelsea Science Festival 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact 17th Oct 2015, Kensington and Chelsea Science Festival, Kensington Town Hall, London. "Tropical diseases: new solutions for tackling old problems": the talk wqas to a braod audience of ~30/40 people, including Major of Kensington/ Chelsea, school children, public and councillors. The talk provoked discussion about the use of insecticides in disase control.
Year(s) Of Engagement Activity 2015
URL https://www.youtube.com/watch?v=dlDmTngEW7w&feature=share
 
Description Keystone Symposia conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact The meeting was focused on One Health and had talks on veterinary and human vaccinology. I was invited to give a talk on the use of viral vectors for co-development of vaccines that can be used in both humans and animals. MERS is an excellent example of one such disease indication.
Year(s) Of Engagement Activity 2016
 
Description Presentation at MRC CiC NTD consortium meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact I gave a presentation on the results of the project of which the MRC CiC was granted for us to complete. In attendance were other grant holders in both academia and industry. Also potential applicants who were actively seeking funding were able to see some of the results and progress of a existing project.
Year(s) Of Engagement Activity 2017